{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:03:31Z","timestamp":1794265411817,"version":"4.9.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-025-01531-4","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:03:14Z","timestamp":1761123794000},"page":"1392-1409","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1897-0649","authenticated-orcid":false,"given":"Yusang","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3650-1822","authenticated-orcid":false,"given":"Goosang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9031-6540","authenticated-orcid":false,"given":"Hyeong-Cheol","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jueng-Hu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8206-8620","authenticated-orcid":false,"given":"Eunhye","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhyeon","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3015-2059","authenticated-orcid":false,"given":"Taebo","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4693-738X","authenticated-orcid":false,"given":"Hyongbum Henry","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"1531_CR1","unstructured":"The Precision Medicine Initiative (The White House, 2015); https:\/\/obamawhitehouse.archives.gov\/precision-medicine"},{"key":"1531_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/S0140-6736(23)02046-9","volume":"402","author":"A Wonkam","year":"2023","unstructured":"Wonkam, A. Are we genetically literate enough for global precision health? Lancet 402, 1123\u20131124 (2023).","journal-title":"Lancet"},{"key":"1531_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun, T. P., Eide, C. A. & Druker, B. J. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 37, 530\u2013542 (2020).","journal-title":"Cancer Cell"},{"key":"1531_CR4","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031\u20131037 (2001).","journal-title":"N. Engl. J. Med."},{"key":"1531_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio, G. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362, 2251\u20132259 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1531_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0780-6","volume":"17","author":"S Soverini","year":"2018","unstructured":"Soverini, S., Mancini, M., Bavaro, L., Cavo, M. & Martinelli, G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol. Cancer 17, 49 (2018).","journal-title":"Mol. Cancer"},{"key":"1531_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-75","volume":"9","author":"JR Sierra","year":"2010","unstructured":"Sierra, J. R., Cepero, V. & Giordano, S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75 (2010).","journal-title":"Mol. Cancer"},{"key":"1531_CR8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1182\/blood.2019002969","volume":"135","author":"S Soverini","year":"2020","unstructured":"Soverini, S. et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood 135, 534\u2013541 (2020).","journal-title":"Blood"},{"key":"1531_CR9","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger, M. W. et al. Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 18, 1385\u20131415 (2020).","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"1531_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02048-y","author":"NCP Cross","year":"2023","unstructured":"Cross, N. C. P. et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia https:\/\/doi.org\/10.1038\/s41375-023-02048-y (2023).","journal-title":"Leukemia"},{"key":"1531_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"1531_CR12","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1016\/j.cell.2021.09.018","volume":"184","author":"PJ Chen","year":"2021","unstructured":"Chen, P. J. et al. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell 184, 5635\u20135652.e5629 (2021).","journal-title":"Cell"},{"key":"1531_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-014-0068-4","volume":"6","author":"E Tosti","year":"2014","unstructured":"Tosti, E. et al. Evolutionarily conserved genetic interactions with budding and fission yeast MutS identify orthologous relationships in mismatch repair-deficient cancer cells. Genome Med. 6, 68 (2014).","journal-title":"Genome Med."},{"key":"1531_CR14","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.cell.2023.03.034","volume":"186","author":"G Yu","year":"2023","unstructured":"Yu, G. et al. Prediction of efficiencies for diverse prime editing systems in multiple cell types. Cell 186, 2256\u20132272.e2223 (2023).","journal-title":"Cell"},{"key":"1531_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41587-021-01039-7","volume":"40","author":"JW Nelson","year":"2022","unstructured":"Nelson, J. W. et al. Engineered pegRNAs improve prime editing efficiency. Nat. Biotechnol. 40, 402\u2013410 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1531_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"1531_CR17","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s41587-022-01276-4","volume":"40","author":"Y Kim","year":"2022","unstructured":"Kim, Y. et al. High-throughput functional evaluation of human cancer-associated mutations using base editors. Nat. Biotechnol. 40, 874\u2013884 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1531_CR18","doi-asserted-by":"publisher","first-page":"7351","DOI":"10.1158\/1078-0432.CCR-17-1745","volume":"23","author":"Y Hu","year":"2017","unstructured":"Hu, Y. et al. Discrimination of germline EGFR T790M mutations in plasma cell-free DNA allows study of prevalence across 31,414 cancer patients. Clin. Cancer Res. 23, 7351\u20137359 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1531_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-018-0461-z","volume":"562","author":"GM Findlay","year":"2018","unstructured":"Findlay, G. M. et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562, 217\u2013222 (2018).","journal-title":"Nature"},{"key":"1531_CR20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/s41587-024-02465-z","volume":"43","author":"Y Kim","year":"2025","unstructured":"Kim, Y., Oh, H.-C., Lee, S. & Kim, H. H. Saturation profiling of drug-resistant genetic variants using prime editing. Nat. Biotechnol. 43, 1471\u20131484 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1531_CR21","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/s41588-024-01800-z","volume":"56","author":"M Buckley","year":"2024","unstructured":"Buckley, M. et al. Saturation genome editing maps the functional spectrum of pathogenic VHL alleles. Nat. Genet. 56, 1446\u20131455 (2024).","journal-title":"Nat. Genet."},{"key":"1531_CR22","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41588-024-01799-3","volume":"56","author":"AJ Waters","year":"2024","unstructured":"Waters, A. J. et al. Saturation genome editing of BAP1 functionally classifies somatic and germline variants. Nat. Genet. 56, 1434\u20131445 (2024).","journal-title":"Nat. Genet."},{"key":"1531_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.08.039","author":"R Olvera-Leon","year":"2024","unstructured":"Olvera-Leon, R. et al. High-resolution functional mapping of RAD51C by saturation genome editing. Cell https:\/\/doi.org\/10.1016\/j.cell.2024.08.039 (2024).","journal-title":"Cell"},{"key":"1531_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrg.2017.117","volume":"19","author":"JJ Salk","year":"2018","unstructured":"Salk, J. J., Schmitt, M. W. & Loeb, L. A. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat. Rev. Genet. 19, 269\u2013285 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"1531_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/nargab\/lqab019","author":"N Stoler","year":"2021","unstructured":"Stoler, N. & Nekrutenko, A. Sequencing error profiles of Illumina sequencing instruments. NAR Genom. Bioinform. 3, https:\/\/doi.org\/10.1093\/nargab\/lqab019 (2021).","journal-title":"NAR Genom. Bioinform."},{"key":"1531_CR26","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.cell.2021.01.012","volume":"184","author":"RE Hanna","year":"2021","unstructured":"Hanna, R. E. et al. Massively parallel assessment of human variants with base editor screens. Cell 184, 1064\u20131080 e1020 (2021).","journal-title":"Cell"},{"key":"1531_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg, E. et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7, 129\u2013141 (2005).","journal-title":"Cancer Cell"},{"key":"1531_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00242","author":"CL Benn","year":"2020","unstructured":"Benn, C. L. & Dawson, L. A. Clinically precedented protein kinases: rationale for their use in neurodegenerative disease. Front. Aging Neurosci. 12, https:\/\/doi.org\/10.3389\/fnagi.2020.00242 (2020).","journal-title":"Front. Aging Neurosci."},{"key":"1531_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature 543, 733\u2013737 (2017).","journal-title":"Nature"},{"key":"1531_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/sj.leu.2404490","volume":"21","author":"FE Nicolini","year":"2007","unstructured":"Nicolini, F. E., Corm, S., Le, Q. H., Roche-Lestienne, C. & Preudhomme, C. The prognosis impact of BCR-ABL P-loop mutations: worse or not worse? Leukemia 21, 193\u2013194 (2007).","journal-title":"Leukemia"},{"key":"1531_CR31","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare, T. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65, 4500\u20134505 (2005).","journal-title":"Cancer Res."},{"key":"1531_CR32","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1182\/blood.V112.11.3220.3220","volume":"112","author":"S Redaelli","year":"2008","unstructured":"Redaelli, S. et al. Determination of the activity profile of bosutinib, dasatinib and nilotinib against 18 imatinib resistant Bcr\/Abl mutants. Blood 112, 3220 (2008).","journal-title":"Blood"},{"key":"1531_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel, A. B., O\u2019Hare, T. & Deininger, M. W. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol. Oncol. Clin. North Am. 31, 589\u2013612 (2017).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"1531_CR34","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli, S. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J. Clin. Oncol. 27, 469\u2013471 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1531_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09048-5","volume":"12","author":"HJG Lindstr\u00f6m","year":"2022","unstructured":"Lindstr\u00f6m, H. J. G. & Friedman, R. Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model. Sci Rep. 12, 5164 (2022).","journal-title":"Sci Rep."},{"key":"1531_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1376","volume":"6","author":"C Benjamin","year":"2023","unstructured":"Benjamin, C., Murugan, S., Hoosen, S. & Rapiti, N. Chronic myeloid leukemia kinase domain mutations: a retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu-Natal, South Africa. Health Sci. Rep. 6, e1376 (2023).","journal-title":"Health Sci. Rep."},{"key":"1531_CR37","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23338","volume":"87","author":"S Redaelli","year":"2012","unstructured":"Redaelli, S. et al. Three novel patient\u2010derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am. J. Hematol. 87, E125 (2012).","journal-title":"Am. J. Hematol."},{"key":"1531_CR38","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide, C. A. et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell 36, 431\u2013443 e435 (2019).","journal-title":"Cancer Cell"},{"key":"1531_CR39","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","volume":"114","author":"S Soverini","year":"2009","unstructured":"Soverini, S. et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 114, 2168\u20132171 (2009).","journal-title":"Blood"},{"key":"1531_CR40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare, T. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16, 401\u2013412 (2009).","journal-title":"Cancer Cell"},{"key":"1531_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0461-8","volume":"15","author":"AM Eiring","year":"2014","unstructured":"Eiring, A. M. & Deininger, M. W. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biol. 15, 461 (2014).","journal-title":"Genome Biol."},{"key":"1531_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/s41587-020-0490-7","volume":"38","author":"RE Hanna","year":"2020","unstructured":"Hanna, R. E. & Doench, J. G. Design and analysis of CRISPR\u2013Cas experiments. Nat. Biotechnol. 38, 813\u2013823 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1531_CR43","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Z Sondka","year":"2024","unstructured":"Sondka, Z. et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 52, D1210\u2013D1217 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1531_CR44","doi-asserted-by":"publisher","unstructured":"Chardon, F. M. et al. A multiplex, prime editing framework for identifying drug resistance variants at scale. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.07.27.550902 (2023).","DOI":"10.1101\/2023.07.27.550902"},{"key":"1531_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02172-9","author":"SI Gould","year":"2024","unstructured":"Gould, S. I. et al. High-throughput evaluation of genetic variants with prime editing sensor libraries. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02172-9 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1531_CR46","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41587-021-01172-3","volume":"40","author":"FJ Sanchez-Rivera","year":"2022","unstructured":"Sanchez-Rivera, F. J. et al. Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants. Nat. Biotechnol. 40, 862\u2013873 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1531_CR47","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1016\/j.molcel.2023.11.021","volume":"83","author":"X Ren","year":"2023","unstructured":"Ren, X. et al. High-throughput PRIME-editing screens identify functional DNA variants in the human genome. Mol. Cell 83, 4633\u20134645 e4639 (2023).","journal-title":"Mol. Cell"},{"key":"1531_CR48","doi-asserted-by":"publisher","first-page":"100814","DOI":"10.1016\/j.xgen.2025.100814","volume":"5","author":"M Herger","year":"2025","unstructured":"Herger, M. et al. High-throughput screening of human genetic variants by pooled prime editing. Cell Genom. 5, 100814 (2025).","journal-title":"Cell Genom."},{"key":"1531_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41592-024-02502-4","volume":"22","author":"A Cirincione","year":"2025","unstructured":"Cirincione, A. et al. A benchmarked, high-efficiency prime editing platform for multiplexed dropout screening. Nat. Methods 22, 92\u2013101 (2025).","journal-title":"Nat. Methods"},{"key":"1531_CR50","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/nmeth.4038","volume":"13","author":"GT Hess","year":"2016","unstructured":"Hess, G. T. et al. Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat. Methods 13, 1036\u20131042 (2016).","journal-title":"Nat. Methods"},{"key":"1531_CR51","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/nmeth.4027","volume":"13","author":"Y Ma","year":"2016","unstructured":"Ma, Y. et al. Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nat. Methods 13, 1029\u20131035 (2016).","journal-title":"Nat. Methods"},{"key":"1531_CR52","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/leu.2016.353","volume":"31","author":"BJ Lee","year":"2017","unstructured":"Lee, B. J. & Shah, N. P. Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors. Leukemia 31, 1096\u20131107 (2017).","journal-title":"Leukemia"},{"key":"1531_CR53","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes, T. P. et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N. Engl. J. Med. 381, 2315\u20132326 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1531_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01860-w","author":"MJ Mauro","year":"2023","unstructured":"Mauro, M. J. et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia https:\/\/doi.org\/10.1038\/s41375-023-01860-w (2023).","journal-title":"Leukemia"},{"key":"1531_CR55","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"A Hochhaus","year":"2023","unstructured":"Hochhaus, A. et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37, 617\u2013626 (2023).","journal-title":"Leukemia"},{"key":"1531_CR56","doi-asserted-by":"publisher","first-page":"B38","DOI":"10.1158\/1557-3265.HEMMAL14-B38","volume":"21","author":"H Tucker","year":"2015","unstructured":"Tucker, H. & Kent, P. Abstract B38: F317i mutation-associated nilotinib resistance in a child with CML: a first report. Clin. Cancer Res. 21, B38 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1531_CR57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1517\/13543784.2011.546344","volume":"20","author":"R Barouch-Bentov","year":"2011","unstructured":"Barouch-Bentov, R. & Sauer, K. Mechanisms of drug resistance in kinases. Expert Opin. Investig. Drugs 20, 153\u2013208 (2011).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1531_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-071320-112701","volume":"90","author":"Y Liu","year":"2021","unstructured":"Liu, Y., Yang, Q. & Zhao, F. Synonymous but not silent: the codon usage code for gene expression and protein folding. Annu. Rev. Biochem. 90, 375\u2013401 (2021).","journal-title":"Annu. Rev. Biochem."},{"key":"1531_CR59","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrg3051","volume":"12","author":"ZE Sauna","year":"2011","unstructured":"Sauna, Z. E. & Kimchi-Sarfaty, C. Understanding the contribution of synonymous mutations to human disease. Nat. Rev. Genet. 12, 683\u2013691 (2011).","journal-title":"Nat. Rev. Genet."},{"key":"1531_CR60","doi-asserted-by":"publisher","unstructured":"Niu, X. et al. Prime editor-based high-throughput screening reveals functional synonymous mutations in human cells. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-025-02710-z (2025).","DOI":"10.1038\/s41587-025-02710-z"},{"key":"1531_CR61","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.cell.2018.06.010","volume":"174","author":"MA Horlbeck","year":"2018","unstructured":"Horlbeck, M. A. et al. Mapping the genetic landscape of human cells. Cell 174, 953\u2013967 e922 (2018).","journal-title":"Cell"},{"key":"1531_CR62","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41592-019-0371-5","volume":"16","author":"RD Chow","year":"2019","unstructured":"Chow, R. D. et al. In vivo profiling of metastatic double knockouts through CRISPR-Cpf1 screens. Nat. Methods 16, 405\u2013408 (2019).","journal-title":"Nat. Methods"},{"key":"1531_CR63","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nmeth.4286","volume":"14","author":"D Du","year":"2017","unstructured":"Du, D. et al. Genetic interaction mapping in mammalian cells using CRISPR interference. Nat. Methods 14, 577\u2013580 (2017).","journal-title":"Nat. Methods"},{"key":"1531_CR64","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nbt.3834","volume":"35","author":"K Han","year":"2017","unstructured":"Han, K. et al. Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions. Nat. Biotechnol. 35, 463\u2013474 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1531_CR65","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","volume":"23","author":"JY Kwak","year":"2017","unstructured":"Kwak, J. Y. et al. Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia. Clin. Cancer Res. 23, 7180\u20137188 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1531_CR66","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian, H. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362, 2260\u20132270 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1531_CR67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187740","author":"Q Jiang","year":"2023","unstructured":"Jiang, Q. et al. Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia chronic-phase (CML-CP) in a registrational randomized phase 2 study. Blood 142, https:\/\/doi.org\/10.1182\/blood-2023-187740 (2023).","journal-title":"Blood"},{"key":"1531_CR68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166452","author":"JE Cortes","year":"2022","unstructured":"Cortes, J. E. et al. Efficacy and safety of vodobatinib in patients (pts) with chronic phase Philadelphia positive chronic myeloid leukemia (Ph plus CML): a sub group analysis by lines of tyrosine kinase inhibitor (TKI) therapy. Blood 140, https:\/\/doi.org\/10.1182\/blood-2022-166452 (2022).","journal-title":"Blood"},{"key":"1531_CR69","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","volume":"27","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase III, randomized, open-label, multi-center FESTnd study. Clin. Cancer Res. 27, 70\u201377 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1531_CR70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150120","author":"AG Turkina","year":"2021","unstructured":"Turkina, A. G. et al. PF-114 in patients failing prior tyrosine kinase-inhibitor therapy including BCR::ABL1T315I. Blood 138, https:\/\/doi.org\/10.1182\/blood-2021-150120 (2021).","journal-title":"Blood"},{"key":"1531_CR71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","volume":"38","author":"S Soverini","year":"2014","unstructured":"Soverini, S. et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk. Res. 38, 10\u201320 (2014).","journal-title":"Leuk. Res."},{"key":"1531_CR72","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1016\/j.clml.2015.02.035","volume":"15","author":"S Soverini","year":"2015","unstructured":"Soverini, S., de Benedittis, C., Mancini, M. & Martinelli, G. Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 15, S120\u2013128 (2015).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"1531_CR73","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"},{"key":"1531_CR74","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568, 511\u2013516 (2019).","journal-title":"Nature"},{"key":"1531_CR75","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax9249","volume":"5","author":"HK Kim","year":"2019","unstructured":"Kim, H. K. et al. SpCas9 activity prediction by DeepSpCas9, a deep learning-based model with high generalization performance. Sci. Adv. 5, eaax9249 (2019).","journal-title":"Sci. Adv."},{"key":"1531_CR76","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1101\/gr.209601.116","volume":"27","author":"T Smith","year":"2017","unstructured":"Smith, T., Heger, A. & Sudbery, I. UMI-tools: modeling sequencing errors in unique molecular identifiers to improve quantification accuracy. Genome Res. 27, 491\u2013499 (2017).","journal-title":"Genome Res."},{"key":"1531_CR77","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473\u20131475 (2014).","journal-title":"Bioinformatics"},{"key":"1531_CR78","unstructured":"Jung, Y. et al. Comprehensive resistance profiling of ABL1 variants against various kinase inhibitors for CML treatment. NCBI Sequence Read Archive https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA1048659 (2023)."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01531-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01531-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01531-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:03:42Z","timestamp":1784239422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-025-01531-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":78,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1531"],"URL":"https:\/\/doi.org\/10.1038\/s41551-025-01531-4","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"13 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Yonsei University has filed a patent application based on this work, in which Y.J., G.Y., H.-C.O. and H.H.K. are listed as inventors. H.H.K. is the founder of cisionMed. T.S. is a stockholder of MagicBulletTherapeutics Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}